Maxim Group initiated coverage on Brooklyn ImmunoTherapeutics with a new price target
$BTX
Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/29/2021 | $9.00 | Overweight | Cantor Fitzgerald |
| 10/6/2021 | $20.00 | Buy | Maxim Group |
4 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)
3 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
BlackRock Technology and Private Equity Term Trust (the "Fund") announced today the final results of the Fund's tender offer (the "Tender Offer") for up to 50% of its outstanding common shares (the "Shares"), which expired on July 8, 2025. The Tender Offer was undersubscribed. Therefore, in accordance with the terms and conditions of the Tender Offer, the Fund will purchase all Shares properly tendered from all tendering shareholders. Payment for Shares tendered and accepted are expected to be made approximately five business days after the pricing date (anticipated to be July 16, 2025). The final results of the Tender Offer are provided in the table below: Fund Name Ticker
BlackRock Technology and Private Equity Term Trust (the "Fund") announced today the expiration and preliminary results of the Fund's tender offer (the "Tender Offer") for up to 50% of its outstanding common shares (the "Shares"). The Tender Offer commenced on June 9, 2025 and expired at 11:59 p.m. Eastern time on July 8, 2025. Based on preliminary information, the number of Shares properly tendered and not withdrawn is noted in the table below. Fund Name Ticker CUSIP Shares Offered for Repurchase Shares Tendered (Preliminary Results) BlackRock Technology and Private Equity Term Trust BTX 09260Q108 106,669,074 96,627,850
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 7/1/2025 Ex-Date- 7/15/2025 Record- 7/15/2025 Payable- 8/1/2025 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Qu
SCHEDULE 13D/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)
SC TO-I/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)
SC TO-I/A - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)
Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00
Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief
Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 7/1/2025 Ex-Date- 7/15/2025 Record- 7/15/2025 Payable- 8/1/2025 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Qu
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 6/2/2025 Ex-Date- 6/13/2025 Record- 6/13/2025 Payable- 7/1/2025 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN